Topics

TOPICS

ANEMIA

Adakveo Approved for Sickle Cell Disease

Modeling Lost Income and Life Expectancy Due to Sickle Cell Disease

BLEEDING DISORDERS

Establishment of ROTEM Sigma Parameters to Evaluate Coagulopathic Bleeding

Updated Guidance on Managing Bleeding and Surgery on Antiplatelet Therapy

GENERAL HEMATOLOGY

RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera

Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea

LEUKEMIA

Corticosteroid-Induced Psychiatric Disorders Are Common in Young Patients With Acute Lymphoblastic Leukemia, Lymphoma

Outcomes Improved for Patients With AML and MDS Receiving Treosulfan/Fludarabine vs Busulfan/Fludarabine Conditioning Prior to HSCT

LYMPHOMA

Trace Metal Concentrations in Specimens of Patients With Lymphoma

Pretreatment Vitamin D Deficiency Associated With Outcomes in Hodgkin Lymphoma

MYELODYSPLASTIC SYNDROMES

An Algorithm for Predicting Resistance to Hypomethylating Agents Using Genomic Biomarkers

Outcomes Based on HSCT Conditioning Regimen for Patients With Myelodysplastic Syndromes

MYELOMA

Hematopoietic Score for Risk Stratification of Newly Diagnosed Multiple Myeloma

Can CAR-T Be Optimized for Multiple Myeloma?

SIDE EFFECT MANAGEMENT

Opioid Therapy for Cancer Pain May Be Associated With High Risk for Aberrant Opioid Use

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

THALASSEMIAS

Improving Bone Mass With Iron Chelation Therapy in Transfusion-Dependent Beta Thalassemia

As Survival Increases in Beta Thalassemia, Renal Complications Emerge

THROMBOTIC DISORDERS

Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines

VTE Risk and Incidence in Hospitalized Patients With Blood Cancers

Next post in Leukemia

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

Outcomes Improved for Patients With AML and MDS Receiving Treosulfan/Fludarabine vs Busulfan/Fludarabine Conditioning Prior to HSCT